Dual Ovarian Stimulation (DUOSTIM) for Poor Ovarian Responders
- Conditions
- Fertility Disorders
- Interventions
- Drug: DUOSTIMDrug: Conventional stimuli
- Registration Number
- NCT03803228
- Lead Sponsor
- Centre Hospitalier Intercommunal Creteil
- Brief Summary
During ovarian stimulation, all the follicles grow under the action of FSH, only the selected follicles and with the faster growth are taken. However during this stimulation, other smaller follicles are also recruited and sensitized, which may increase the selection of follicles available on the follicular wave following. In patients with weak reserve this potentiation has a great interest, and the sequence of 2 stimulations on the same cycle could make it possible to obtain a larger number of oocytes and embryos, thus giving a better chance of delivery than on 2 distinct cycles of stimulation. However, this is preliminary data that needs to be confirmed with a randomized controlled trial. In this population of poor prognosis, the use of FSH-associated LH activity may optimize the ovarian response to stimulation, particularly the combination containing placental HCG (Fertistartkit®) that obtaining a slightly higher number of oocytes than highly purified HMG (Menopur®).
- Detailed Description
Ovarian stimulation is an essential prerequisite for any in vitro fertilization attempt (IVF) to optimize the chances of delivery per cycle. These depend in the first place on the age of the patients and secondly on the number of oocytes collected. There is a strong correlation between these two factors, the ovarian reserve diminishing with age. In older patients or patients with decreased reserve, however, the number of oocytes collected remains a prognostic factor for the chances of delivery.
At the present time, there is no validated intervention that would bring a significant interest on the number of oocytes obtained in the group of bad responder patients. However, it is a very heterogeneous population whose definition has been proposed only recently, the Bologna criteria and questioned by a new proposal from the Poseidon group. The latter is more focused on the prognosis of success, differentiating patients with a diminished reserve (count of antral follicles CFA \<5 and / or AMH \<1.2 ng / ml) from those with an "unexpected" bad response. As the profiles are better defined, it is easier to determine the impact of a strategy in a specific group.
Recent clarifications on the ovarian cycle and folliculogenesis have shown that several waves of follicular development coexist on the same cycle and that it is perfectly possible to obtain a follicular development with a luteal phase equivalent oocyte quality, compared to conventional stimulations performed in the follicular phase. The main constraint of luteal phase stimulation is the lack of possibility of fresh transfer due to non-synchronization with the endometrium. This constraint is today secondary given the evolution of conservation techniques with the development of embryonic and oocyte vitrification.
On the other hand, there is a differential dependence of FSH follicles, their sensitivity depending on the number of FSH receptors and their duration of exposure to FSH. During ovarian stimulation, all the follicles grow under the action of FSH, only the selected follicles and with the faster growth are taken. However during this stimulation, other smaller follicles are also recruited and sensitized, which may increase the selection of follicles available on the follicular wave following. In patients with weak reserve this potentiation has a great interest, and the sequence of 2 stimulations on the same cycle could make it possible to obtain a larger number of oocytes and embryos, thus giving a better chance of delivery than on 2 distinct cycles of stimulation. However, this is preliminary data that needs to be confirmed with a randomized controlled trial. In this population of poor prognosis, the use of FSH-associated LH activity may optimize the ovarian response to stimulation, particularly the combination containing placental HCG (Fertistartkit®) that obtaining a slightly higher number of oocytes than highly purified HMG (Menopur®).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 88
- Women from 20 to 41 years old
- CFA <5 and / or AMH <1, 2 ng / ml
- 19 ≤ BMI ≤ 32
- Supports IVF or ICSI
- If antecedent IVF / ICSI, number of oocytes collected <4
- Attack rank (puncture with transfer) <3
- Affiliation to the general social security scheme and benefiting from 100% infertility
- Confirmed ovarian insufficiency (amenorrhea)
- FSH> 20 IU / l or CFA <1
- Puncture rank> 3
- Azoospermia or cryptozoospermia
- Against indication to ovarian stimulation
- Presence of a cyst of indeterminate etiology, ovarian, uterine or mammary carcinoma, hypothalamic or pituitary tumors
- Hypersensitivity to any of the medicines in the protocol
- Moderate or severe pathology of renal or hepatic function
- Evolutionary thromboembolic accidents
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description DUOSTIM DUOSTIM (stim 1) flexible antagonist protocol with pre-treatment with estrogen (S1 between J1 and J8 under E2) and stimulation with Fertistartkit® 300 IU / d; triggering by rHCG (Ovitrelle®250μg) and puncture at 36h; oocyte freezing; (stim 2) resumption of stimulation only by Fertistratkit® 300 IU / day from the day after the puncture; introduction of Progestan® 7 days later to avoid menstruation during the second puncture; triggering with rHCG and second puncture at 36h associated with the devitrification of stim 1 oocytes, with sperm collection and embryonic vitrification. Transfer of frozen embryos to the subsequent cycle in the natural cycle (without HCG) and until the frozen embryos are exhausted. Conventional stimuli Conventional stimuli (stim 1) flexible antagonist protocol with pre-treatment with estrogen (S1 between J1 and J8 under E2) and stimulation with Fertistartkit® 300 IU / d; triggering by rHCG (Ovitrelle®250μg) and puncture at 36h; fresh embryonic transfer if satisfactory endometrial conditions with luteal phase support by vaginal micronized progesterone Progestan® 600 mg / d; otherwise embryonic freezing and transfer of frozen embryos to the subsequent cycle in the natural cycle until the frozen embryos are exhausted. (stim 2) ditto starting on the next cycle if possible or the next one. Hormonal Controls + Ultrasound During Stimulation: Blocking / S1 - S5 / S6 - S8 / S9 - SHCG / SHCG-1
- Primary Outcome Measures
Name Time Method cumulative number of oocytes on 2 punctures up to 60 days cumulative number of oocytes on 2 punctures
- Secondary Outcome Measures
Name Time Method number of embryos transferred up to 60 days number of embryos transferred
cumulative number of oocytes in metaphase II up to 60 days cumulative number of oocytes in metaphase II
number of frozen embryos 1.5 month number of frozen embryos
dose of FSH up to 60 days cumulative total dose of FSH
the number of stimulation days up to 20 days the number of stimulation days
cumulative number of follicles> 14mm up to 60 days cumulative number of follicles\> 14mm
cumulative number of embryos obtained 1 month cumulative number of embryos obtained
estradiol level up to 20 days estradiol level
LH level up to 20 days LH level
progesterone level up to 20 days progesterone level
transfer rate 3 months cancellation or no transfer rate
rates of early pregnancy up to 9 months cumulative rates of early pregnancy (HCG\> 100) and ultrasound (6-7SA)
number of beginner pregnancy up to 9 months number of beginner pregnancy in each groups
cumulative cost up to 9 months cumulative cost of 2 attempts including frozen embryo transfers (treatments, consultations, MPA laboratory and monitoring exams)
Side effects up to 9 months reported side effects
Trial Locations
- Locations (4)
Polyclinique Saint Roch
🇫🇷Montpellier, France
CHI Creteil
🇫🇷Créteil, France
Polyclinique Jean Villar
🇫🇷Bruges, France
Cabinet Médical Carré Saint Giniez
🇫🇷Marseille, France